152 related articles for article (PubMed ID: 16757696)
21. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
Ganz PA; Land SR
Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
[TBL] [Abstract][Full Text] [Related]
22. SERMs: meeting the promise of multifunctional medicines.
Jordan VC
J Natl Cancer Inst; 2007 Mar; 99(5):350-6. PubMed ID: 17341726
[TBL] [Abstract][Full Text] [Related]
23. U.S. Food and drug administration analysis of strokes associated with raloxifene.
Wyeth J; Green L; Avigan M
Obstet Gynecol; 2007 Apr; 109(4):999. PubMed ID: 17400869
[No Abstract] [Full Text] [Related]
24. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
Sestak I; Kealy R; Edwards R; Forbes J; Cuzick J
J Clin Oncol; 2006 Aug; 24(24):3991-6. PubMed ID: 16921052
[TBL] [Abstract][Full Text] [Related]
25. Raloxifene and its role in breast cancer prevention.
Eng-Wong J; Zujewski JA
Expert Rev Anticancer Ther; 2004 Aug; 4(4):523-32. PubMed ID: 15270657
[TBL] [Abstract][Full Text] [Related]
26. Chemoprevention of breast cancer.
Thomsen A; Kolesar JM
Am J Health Syst Pharm; 2008 Dec; 65(23):2221-8. PubMed ID: 19020189
[TBL] [Abstract][Full Text] [Related]
27. Raloxifene (Evista) for breast cancer prevention in postmenopausal women.
Med Lett Drugs Ther; 2006 May; 48(1234):37. PubMed ID: 16685245
[TBL] [Abstract][Full Text] [Related]
28. Re: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
Yalcin B; Buyukcelik A; Yalcin S; Utkan G; Doruk H; Dogan M; Altan M
J Natl Cancer Inst; 2005 Apr; 97(7):542; author reply 542-3. PubMed ID: 15812082
[No Abstract] [Full Text] [Related]
29. Randomized clinical trials of raloxifene: reducing the risk of osteoporosis and breast cancer in postmenopausal women.
Olevsky OM; Martino S
Menopause; 2008; 15(4 Suppl):790-6. PubMed ID: 18596600
[TBL] [Abstract][Full Text] [Related]
30. [The interruption of a study following an "ad interim" analysis. The example of the NSABP-P1 study].
Savarese A
Suppl Tumori; 2004; 3(4):S23-4. PubMed ID: 15206204
[No Abstract] [Full Text] [Related]
31. [Breast cancer chemoprevention. Rational, trials results and future].
Cutuli B; Lesur A; Namer M; Kerbrat P
Bull Cancer; 2009 May; 96(5):519-30. PubMed ID: 19467983
[TBL] [Abstract][Full Text] [Related]
32. Raloxifene and prevention of vertebral fracture (cont'd): mainly when oestrogen is contraindicated.
Prescrire Int; 2000 Dec; 9(50):190-1. PubMed ID: 11475503
[TBL] [Abstract][Full Text] [Related]
33. Re: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Cuzick J; Forbes JF; Howell A
J Natl Cancer Inst; 2006 May; 98(9):643; author reply 643-4. PubMed ID: 16670391
[No Abstract] [Full Text] [Related]
34. Selective estrogen-receptor modulators for primary prevention of breast cancer.
Fabian CJ; Kimler BF
J Clin Oncol; 2005 Mar; 23(8):1644-55. PubMed ID: 15755972
[No Abstract] [Full Text] [Related]
35. Tamoxifen prevention of breast cancer: an instance of the fingerpost.
Lippman SM; Brown PH
J Natl Cancer Inst; 1999 Nov; 91(21):1809-19. PubMed ID: 10547388
[No Abstract] [Full Text] [Related]
36. Does hormonal therapy decrease tamoxifen associated hot flashes?
Barton DL; Loprinzi CL
Breast Cancer Res Treat; 2009 Aug; 116(3):529-30. PubMed ID: 19205876
[No Abstract] [Full Text] [Related]
37. Tamoxifen and the factor V Leiden mutation.
Cuzick J
J Natl Cancer Inst; 2010 Jul; 102(13):918-9. PubMed ID: 20554943
[No Abstract] [Full Text] [Related]
38. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial.
Bonanni B; Macis D; Maisonneuve P; Johansson HA; Gucciardo G; Oliviero P; Travaglini R; Muraca MG; Rotmensz N; Veronesi U; Decensi AU
J Clin Oncol; 2006 Aug; 24(22):3708-9; author reply 3709. PubMed ID: 16877740
[No Abstract] [Full Text] [Related]
39. The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer.
Osborne CR; Duncan A; Sedlacek S; Paul D; Holmes F; Vukelja S; Kasper M; Wilks S; Schneider A; McGee R; Meyer WG; O'Shaughnessy JA
Breast Cancer Res Treat; 2009 Aug; 116(3):521-7. PubMed ID: 19139988
[TBL] [Abstract][Full Text] [Related]
40. [Hormone therapy for uterine corpus cancer--introduction].
Sugiyama T; Izutsu T
Nihon Rinsho; 2004 Oct; 62 Suppl 10():370-4. PubMed ID: 15535270
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
